Compare Gilead Sciences, Inc. (GILD) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Uber Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $133.16 (market cap $163.51B), while Uber Technologies Inc trades at $73.99 (market cap $147.93B). The key difference: Gilead Sciences, Inc. and Uber Technologies Inc are close in size by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| GILD | UBER | |
|---|---|---|
Market Cap | $163.51B | $147.93B |
Sector | Health | Industrials |
52-Week High | $155.80 | $100.10 |
52-Week Low | $108.22 | $68.61 |
Enterprise Value | $178.05B | $154.25B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Uber Technologies (UBER) trades at $72.08, down 2.94% today, amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $52.02B revenue and $10.05B net income, though 2026 projections show moderating growth. Recent news highlights strategic shifts toward autonomous vehicles with robotaxi pilots in Madrid and Munich, alongside cost-cutting measures including HR layoffs. Analyst consensus remains strongly bullish with an $108.92 price target, representing 51% upside potential from current levels.
Uber presents a compelling growth story with expanding profitability and market dominance, though near-term technical weakness and moderating 2026 earnings projections warrant caution. The autonomous vehicle expansion represents significant long-term opportunity, while competitive pressures and regulatory risks persist. With zero sell ratings and overwhelming analyst support, the stock appears fundamentally undervalued despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
